Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring

Purpose In glycogen storage disease type III (GSD III), liver aminotransferases tend to normalize with age giving an impression that hepatic manifestations improve with age. However, despite dietary treatment, long-term liver complications emerge. We present a GSD III liver natural history study in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Genetics in medicine 2019-12, Vol.21 (12), p.2686-2694
Hauptverfasser: Halaby, Carine A., Young, Sarah P., Austin, Stephanie, Stefanescu, Ela, Bali, Deeksha, Clinton, Lani K., Smith, Brian, Pendyal, Surekha, Upadia, Jariya, Schooler, Gary R., Mavis, Alisha M., Kishnani, Priya S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose In glycogen storage disease type III (GSD III), liver aminotransferases tend to normalize with age giving an impression that hepatic manifestations improve with age. However, despite dietary treatment, long-term liver complications emerge. We present a GSD III liver natural history study in children to better understand changes in hepatic parameters with age. Methods We reviewed clinical, biochemical, histological, and radiological data in pediatric patients with GSD III, and performed a literature review of GSD III hepatic findings. Results Twenty-six patients (median age 12.5 years, range 2–22) with GSD IIIa ( n  = 23) and IIIb ( n  = 3) were enrolled in the study. Six of seven pediatric patients showed severe fibrosis on liver biopsy (median [range] age: 1.25 [0.75–7] years). Markers of liver injury (aminotransferases), dysfunction (cholesterol, triglycerides), and glycogen storage (glucose tetrasaccharide, Glc 4 ) were elevated at an early age, and decreased significantly thereafter ( p  
ISSN:1098-3600
1530-0366
DOI:10.1038/s41436-019-0561-7